These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17712256)

  • 1. Evaluating chronic disease for heterogeneous populations: the case of arthritis.
    Scharff RL; Jessup A
    Med Care; 2007 Sep; 45(9):860-8. PubMed ID: 17712256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live long, live well: quantifying the health of heterogeneous populations.
    Mullahy J
    Health Econ; 2001 Jul; 10(5):429-40. PubMed ID: 11466804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
    Konnopka A; Conrad K; Baerwald C; König HH
    Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life measurements and studies in rheumatoid arthritis.
    Lubeck DP
    Am J Manag Care; 2002 Sep; 8(9):811-20. PubMed ID: 12234022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality-adjusted life years lost from nonfatal motor vehicle accident injuries.
    Nyman JA; Barleen NA; Kirdruang P
    Med Decis Making; 2008; 28(6):819-28. PubMed ID: 19015290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of community-based physical activity interventions.
    Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
    Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of the Expert Patients Programme (EPP) for patients with chronic conditions.
    Richardson G; Kennedy A; Reeves D; Bower P; Lee V; Middleton E; Gardner C; Gately C; Rogers A
    J Epidemiol Community Health; 2008 Apr; 62(4):361-7. PubMed ID: 18339831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?
    Van Houtven G; Powers J; Jessup A; Yang JC
    Health Econ; 2006 Aug; 15(8):775-95. PubMed ID: 16544361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey.
    Franic DM; Pathak DS; Gafni A
    J Clin Epidemiol; 2005 Mar; 58(3):291-303. PubMed ID: 15718119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring disability and quality of life in established rheumatoid arthritis.
    Lillegraven S; Kvien TK
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):827-40. PubMed ID: 17870030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
    Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
    J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.